fashion -WSS

fashion

author：leisure time 2025-09-06 09:48:24 - browse：8

The corporate offices of Massachusetts General Brigham hospitals in Assembly Square in Somerville. Lane Turner/Globe Staff

The severing of ties between two of Boston’s biggest health care giants has placed one of the nation’s largest health care systems in the position of figuring out how, exactly, to fill a new hole in its oncology services, at a time when cancer care is changing rapidly.

Earlier this month, Dana-Farber Cancer Institute surprised the medical community and even its partner, Brigham and Women’s Hospital, when it announced that it would end their nearly 30-year collaboration. The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians.

Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives. The two parties had been in discussions about extending their contract for months when the split was announced. “The decision was made by the Farber. It was announced. Now, we just have to plan forward,” she said. Klibanski shared her views on the split at a meeting with Boston Globe opinion editors on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： CEOs share strategies for surviving biotech slump

explore

WSS

Flu, Covid vaccination rates decline, new survey data show

The EU Joint Clinical Assessment needs to live up to its promise

Hospital price transparency does save money, advocate argues

Lawmakers consider Medicare pay reforms for doctors

FDA struggles to regulate food additives, sometimes for decades

The explosion of genetic testing requires a new approach

knowledge

fashion

focus

Continuity nursing helped my family in our darkest PICU moments

STAT Readout Newsletter: Today's biggest biotech updates

In Memoriam: Notable people who died in 2023

Solve the antibiotic resistance crisis with preventive drugs

In Memoriam: Notable people who died in 2023

Some top drug companies are starting to take action on climate

United colonoscopy coverage change 'may cost lives,' doctors say

Stop Congress from blocking public access to science

Medicare details structure of new drug price negotiation program

Beam Therapeutics to lay off 20% of its staff, re

focus

Solve the antibiotic resistance crisis with preventive drugs

European officials brace for rough respiratory virus season

The United States is paying nearly triple for new Covid vaccines

Health insurers' Q3 question: how much care are people getting?

How climate

HHS leader on health, climate change and biopharma emissions

leisure time

explore

hotspot

hotspot